Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Boston, MA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Cleveland, OH
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Miami, FL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Lake Success, NY
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Memphis, TN
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
San Antonio, TX
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Birmingham, AL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Stanford, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Orlando, FL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Atlanta, GA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Chicago, IL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Covington, LA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Covington, LA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Burlington, MA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Rochester, MN
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Morristown, NJ
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
New York, NY
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Nashville, TN
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Seattle, WA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Washington,
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
Lowell General Hospital
mi
from
Lowell, MA
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
Lowell General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2018
South Shore Hospital
mi
from
South Weymouth, MA
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2018
South Shore Hospital
mi
from
South Weymouth, MA
Click here to add this to my saved trials
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study
Status: Enrolling
Updated:  2/12/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study
Status: Enrolling
Updated: 2/12/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  2/13/2018
Stanford University
mi
from
Palo Alto, CA
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 2/13/2018
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  2/13/2018
University of Miami
mi
from
Miami, FL
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 2/13/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
AT13387 in Adults With Refractory Solid Tumors
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
Status: Enrolling
Updated:  2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AT13387 in Adults With Refractory Solid Tumors
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
Status: Enrolling
Updated: 2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Status: Enrolling
Updated:  2/13/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Status: Enrolling
Updated: 2/13/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Arnett Cancer Care
mi
from
Lafayette, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Arnett Cancer Care
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Horizon Oncology Center
mi
from
Lafayette, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Medical Consultants, P.C.
mi
from
Muncie, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Ireland Cancer Center - University Hospitals of Cleveland
mi
from
Cleveland, OH
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Ireland Cancer Center - University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Anaheim, CA
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Gainesville, FL
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Miami, FL
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
New Port Richey, FL
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials